AbCellera Reports Q3 2026 Business Results
Key Highlights
- ➤ABCL635 Phase 2 data showed significant reductions in moderate and severe hot flashes
- ➤$200 million offering lifted total available liquidity above $890 million
- ➤Q3 revenue reached $10.6 million, up from $9.0 million year over year
- ➤Q3 net loss narrowed to $40.8 million from $57.1 million
- ➤ABCL575 Phase 1 met all endpoints; AbCellera will not develop it past Phase 1
Expert Statements
Carl Hansen, Ph.D., Founder and CEO of AbCellera
“This was a transformative quarter for AbCellera, highlighted by strong clinical execution and balance sheet expansion. Positive top-line Phase 2 results for ABCL635 demonstrated an efficacy and tolerability profile that has potential to redefine the treatment of hot flashes. On the strength of this data, we raised $200 million, bringing our available liquidity to approximately $900 million.”
Carl Hansen, Ph.D., Founder and CEO of AbCellera
“Together with the top-line Phase 1 readout of ABCL575 and the addition of three new pipeline programs, ABCL992, ABCL385, and ABCL646, we have delivered on all corporate priorities for 2026.”
AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2026. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
“This was a transformative quarter for AbCellera, highlighted by strong clinical execution and balance sheet expansion. Positive top-line Phase 2 results for ABCL635 demonstrated an efficacy and tolerability profile that has potential to redefine the treatment of hot flashes. On the strength of this data, we raised $200 million, bringing our available liquidity to approximately $900 million,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. “Together with the top-line Phase 1 readout of ABCL575 and the addition of three new pipeline programs, ABCL992, ABCL385, and ABCL646, we have delivered on all corporate priorities for 2026.”
Get started
Create a free account to read the full story.